All productsSemaglutide
Size
- 10 mg — $60.00 CAD — Available
Research focus
A GLP-1 analogue studied for metabolic regulation in controlled human trials.
In simple words
Semaglutide is a peptide modelled on GLP-1, a gut hormone involved in metabolic signalling. Controlled human studies examine body-weight and metabolic responses in specific populations.
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
Research references
Reviewed 2026-10-26
Human — randomized controlled trial
1,961 adults with overweight or obesity, without diabetes.
Semaglutide plus lifestyle intervention produced greater weight reduction than placebo plus lifestyle intervention over 68 weeks.
Nausea and diarrhoea were common. More participants stopped semaglutide because of gastrointestinal events. The tested formulation and trial setting matter.
PMID 33567185. Indexed abstract checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Resources
Compound name and formula checked via PubChem PUG REST. This reference does not verify the vial, salt or formulation.
PubChemMechanism and target search. Automated access returned 403; DrugBank was not used to substantiate claims or approval status.
DrugBankProtein/precursor search, not a record of the supplied vial. Synthetic compounds and lab supplies may have no matching protein entry.
UniProtBioactivity search. Assay results depend on the tested compound, target and experimental conditions.
ChEMBLExplore indexed literature. Search results are not supporting citations; selected verified publications appear above.
PubMedExplore registrations. A match or completed study does not establish efficacy, approval or relevance to this vial.
ClinicalTrials.govExact preferred-name record verified through the ChEMBL API; activity records require their own assay context.
ChEMBL — semaglutideReviewed human GLP1R record verified via UniProt API. This is a receptor record, not compound identity or evidence of vial activity.
UniProt — human GLP-1 receptorEvidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Research questions about Semaglutide
What is Semaglutide?
Semaglutide is a peptide modelled on GLP-1, a gut hormone involved in metabolic signalling. Controlled human studies examine body-weight and metabolic responses in specific populations.
What types of research are cited for Semaglutide?
The Semaglutide profile contains the following selected evidence. This is not a systematic review or a complete inventory of research.
Semaglutide: STEP 1 (2021): Human — randomized controlled trial
Publication: Semaglutide: STEP 1Who or what was studied in the selected Semaglutide references?
Semaglutide: STEP 1 (2021): 1,961 adults with overweight or obesity, without diabetes.
Publication: Semaglutide: STEP 1What identity distinctions matter for Semaglutide?
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
What do the selected Semaglutide studies not establish?
Semaglutide: STEP 1 (2021): Nausea and diarrhoea were common. More participants stopped semaglutide because of gastrointestinal events. The tested formulation and trial setting matter.
Publication: Semaglutide: STEP 1These studies do not establish the identity, purity, safety or effects of the MXC Semaglutide vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.